Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Ritz

Showing results (291-300 of 315) with videos related to

Pageof 32
Sort By:
The Journal of Clinical Investigation|October 2, 2014
Ibrutinib treatment ameliorates murine chronic graft-versus-host diseaseJason A Dubovsky, Ryan Flynn, Jing Du, et al.
The Journal of Clinical Investigation|August 6, 2013
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsUte E Burkhardt, Ursula Hainz, Kristen Stevenson, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell TransplantationRobert J Soiffer, Haesook T Kim, Joseph McGuirk, et al.
The New England Journal of Medicine|July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
The Journal of Clinical Investigation|March 29, 2022
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapseRoman M Shapiro, Grace C Birch, Guangan Hu, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Blood|February 28, 2022
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesMichael C Zaiken, Ryan Flynn, Katelyn G Paz, et al.
Nature Biotechnology|August 21, 2024
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantationNicoletta Cieri, Nidhi Hookeri, Kari Stromhaug, et al.
Pageof 32

Showing results (291-300 of 315) with videos related to

Sort By:
Pageof 32
The Journal of Clinical Investigation|October 2, 2014
Ibrutinib treatment ameliorates murine chronic graft-versus-host diseaseJason A Dubovsky, Ryan Flynn, Jing Du, et al.
The Journal of Clinical Investigation|August 6, 2013
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsUte E Burkhardt, Ursula Hainz, Kristen Stevenson, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell TransplantationRobert J Soiffer, Haesook T Kim, Joseph McGuirk, et al.
The New England Journal of Medicine|July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
The Journal of Clinical Investigation|March 29, 2022
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapseRoman M Shapiro, Grace C Birch, Guangan Hu, et al.
Blood|May 23, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesMatthew J Frigault, Charlotte E Graham, Trisha R Berger, et al.
Blood|February 28, 2022
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesMichael C Zaiken, Ryan Flynn, Katelyn G Paz, et al.
Nature Biotechnology|August 21, 2024
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantationNicoletta Cieri, Nidhi Hookeri, Kari Stromhaug, et al.
Pageof 32